IRF8 and leukemia: Evidence has suggested that IRF8 acts as a TSG in multiple cancers, including leukemia, renal cancer, and soft tissue sarcoma, via regulating cell proliferation, apoptosis, cell cycle distribution, cell invasion, and metastasis [16, 17, 28].